Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MGI Pharma Saforis “Approvable” Letter Seeks More Data

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA is asking the company to conduct an additional Phase III trial to establish efficacy of oral mucositis therapy.

You may also be interested in...



Saforis Granted Priority Review

MGI Pharma's Saforis (glutamine in UpTec powder for oral suspension) has a user fee date of Oct. 12 under a priority review, the firm said June 12

MGI/SuperGen’s Dacogen On Deck For Late May Launch

The myelodysplastic syndromes therapy could post $25 mil. in 2006 sales, MGI said following the May 3 approval.

MGI’s Oral Mucositis Therapy Saforis NDA Submitted

The firm had planned to file the application for glutamine in the third quarter of 2005.

Related Content

Topics

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel